Active targeted ligand-aza-BODIPY conjugate for near-infrared photodynamic therapy in melanoma
- 15 April 2020
- journal article
- research article
- Published by Elsevier BV in International Journal of Pharmaceutics
- Vol. 579, 119189
- https://doi.org/10.1016/j.ijpharm.2020.119189
Abstract
No abstract availableFunding Information
- Postgraduate Research Grant (PPP) – Research (PG222-2016A)
- Fujian Provincial Natural Science Foundation (2017J01577)
- Thailand Research Fund
- Office of the Higher Education Commission (MRG6180030)
This publication has 84 references indexed in Scilit:
- Melanoma resistance to photodynamic therapy: new insightsBiological Chemistry, 2013
- Targeting PD-1/PD-L1 interactions for cancer immunotherapyOncoImmunology, 2012
- Search for inhibitors of endocytosisCellular Logistics, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Neurotrophins in lung health and diseaseExpert Review of Respiratory Medicine, 2010
- c-Src Is Required for Tropomyosin Receptor Kinase C (TrkC)-induced Activation of the Phosphatidylinositol 3-Kinase (PI3K)-AKT PathwayOnline Journal of Public Health Informatics, 2008
- A Combinatorial Method for Solution-Phase Synthesis of Labeled Bivalent β-Turn MimicsJournal of the American Chemical Society, 2007
- In situ photoimmunotherapy: a tumour-directed treatment for melanomaBritish Journal of Dermatology, 2006
- Neurotrophins in Skin Biology and PathologyJournal of Investigative Dermatology, 2006
- A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancerNature Genetics, 2005